Anzeige
Mehr »
Dienstag, 24.06.2025 - Börsentäglich über 12.000 News
Einmalige Gelegenheit?: Eines der aufregendsten Junior-Goldexplorationsprojekte in Australien im Fokus!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: 853849 | ISIN: JP3463000004 | Ticker-Symbol: TKD
Tradegate
23.06.25 | 16:27
25,550 Euro
+0,24 % +0,060
Branche
Chemie
Aktienmarkt
NIKKEI-225
Singapur
1-Jahres-Chart
TAKEDA PHARMACEUTICAL CO LTD Chart 1 Jahr
5-Tage-Chart
TAKEDA PHARMACEUTICAL CO LTD 5-Tage-Chart
RealtimeGeldBriefZeit
25,29025,69023.06.
25,35025,60023.06.

Aktuelle News zur TAKEDA PHARMACEUTICAL Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
TAKEDA PHARMACEUTICAL Aktie jetzt für 0€ handeln
17.06.With FDA nod for HAE drug Andembry, CSL set to compete with Takeda's Takhzyro6
17.06.Takeda's VP to Quit Japanese Drugmaker to Join Chinese Rival BeiGene, Sources Say11
12.06.TAKEDA PHARMACEUTICAL COMPANY LIMITED: GENERAL ANNOUNCEMENT::SHARE REPURCHASE REPORT (FROM MAY 1, 2025 TO MAY 31, 2025)3
10.06.TAKEDA PHARMACEUTICAL COMPANY LIMITED: GENERAL ANNOUNCEMENT::NOTICE CONCERNING DISPOSAL OF TREASURY SHARES - LTIP FOR COMPANY GROUP EMPLOYEE OUTSIDE OF JAPAN4
06.06.TAKEDA PHARMACEUTICAL CO LTD - 6-K, Report of foreign issuer6
06.06.TAKEDA PHARMACEUTICAL COMPANY LIMITED: GENERAL ANNOUNCEMENT::STATEMENT CHAIR OF TAKEDA BOD IN RESPONSE TO ISS VOTING RECOMMENDATIONS AHEAD OF THE ORDINARY GMS3
05.06.EQS Newswire: Best Places to Work: Takeda Ukraine & Bulgaria Earn #8 Global Ranking in Best Places to Work 2024402EQS Newswire / 05/06/2025 / 11:30 CET/CEST LONDON, UK - Media OutReach Newswire - 5 June 2025 - Takeda, a global value-based, R&D-driven biopharmaceutical company, has been proudly recognized...
► Artikel lesen
04.06.Takeda receives EC approval for Adcetris combination in Hodgkin lymphoma15
04.06.EC approves Takeda ADC plus chemo for stage IIb Hodgkin's lymphoma10
03.06.Takeda, Pfizer's Adcetrix wins EU approval for hodgkin lymphoma treatment16
03.06.Takeda's ADCETRIS Combo Approved In EU For Advanced Hodgkin Lymphoma349TOKYO (dpa-AFX) - Takeda (TAK), Tuesday announced that the European Commission has approved ADCETRIS combined with etoposide, cyclophosphamide, doxorubicin, dacarbazine, and dexamethasone for...
► Artikel lesen
03.06.EU approves Takeda's new Hodgkin lymphoma treatment3
03.06.Takeda Pharmaceutical Company Limited: European Commission Approves ADCETRIS (brentuximab vedotin) for the Treatment of Adult Patients with Newly Diagnosed Stage IIb/III/IV Hodgkin Lymphoma in Combination with ECADD508Approval Based on Positive Results from the Phase 3 HD21 Trial for Stage IIb with Risk Factors/III/IV Hodgkin Lymphoma ADCETRIS-based Combination Demonstrated Superior Safety Profile and Efficacy...
► Artikel lesen
03.06.Infrareal übernimmt Takedas Pharma- und Biotech-Standort in Orth6
02.06.TAKEDA PHARMACEUTICAL COMPANY LIMITED: GENERAL ANNOUNCEMENT::WITHDRAWAL OF SHELF REGISTRATION STATEMENT AND FILING OF NEW SHELF REGISTRATION STATEMENT IN JAPAN8
02.06.TAKEDA PHARMACEUTICAL COMPANY LIMITED: GENERAL ANNOUNCEMENT::ASCO PLENARY PRESENTATION HIGHLIGHTING FULL 32-WEEK RESULTS FROM PHASE 3 VERIFY STUDY OF RUSFERTIDE13
28.05.Takeda reicht Bericht zur Vergütung von Führungskräften bei der SEC ein5
28.05.TAKEDA PHARMACEUTICAL CO LTD - 6-K, Report of foreign issuer2
28.05.TAKEDA PHARMACEUTICAL COMPANY LIMITED: GENERAL ANNOUNCEMENT::TAKEDA EXECUTIVE COMPENSATION OVERVIEW-
28.05.TAKEDA PHARMACEUTICAL COMPANY LIMITED: GENERAL ANNOUNCEMENT::CEO SHAREHOLDER LETTER 20251
Weiter >>
145 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1